Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.20EUR
−12.05 MEUR
1.25 MEUR
52.06 M
About IGC Pharma, Inc.
Sector
Industry
CEO
Ram Mukunda
Website
Headquarters
Potomac
Employees (FY)
67
Founded
2005
FIGI
BBG000W6KF77
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IGS1 is 0.40 EUR — it has decreased by 2.94% in the past 24 hours. Watch IGC PHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange IGC PHARMA INC stocks are traded under the ticker IGS1.
IGS1 stock has risen by 6.45% compared to the previous week, the month change is a 13.54% fall, over the last year IGC PHARMA INC has showed a 32.00% increase.
We've gathered analysts' opinions on IGC PHARMA INC future price: according to them, IGS1 price has a max estimate of 2.99 EUR and a min estimate of 2.99 EUR. Watch IGS1 chart and read a more detailed IGC PHARMA INC stock forecast: see what analysts think of IGC PHARMA INC and suggest that you do with its stocks.
IGS1 reached its all-time high on Apr 4, 2024 with the price of 0.83 EUR, and its all-time low was 0.23 EUR and was reached on Dec 13, 2023. View more price dynamics on IGS1 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IGS1 stock is 3.03% volatile and has beta coefficient of 0.15. Track IGC PHARMA INC stock price on the chart and check out the list of the most volatile stocks — is IGC PHARMA INC there?
Today IGC PHARMA INC has the market capitalization of 30.66 M, it has increased by 17.14% over the last week.
Yes, you can track IGC PHARMA INC financials in yearly and quarterly reports right on TradingView.
IGC PHARMA INC is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
IGS1 earnings for the last quarter are −0.04 EUR per share, whereas the estimation was −0.04 EUR resulting in a 0% surprise. The estimated earnings for the next quarter are −0.04 EUR per share. See more details about IGC PHARMA INC earnings.
IGC PHARMA INC revenue for the last quarter amounts to 178.87 K EUR, despite the estimated figure of 178.87 K EUR. In the next quarter, revenue is expected to reach 581.13 K EUR.
IGS1 net income for the last quarter is −2.67 M EUR, while the quarter before that showed −5.06 M EUR of net income which accounts for 47.20% change. Track more IGC PHARMA INC financial stats to get the full picture.
No, IGS1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 30, 2024, the company has 67.00 employees. See our rating of the largest employees — is IGC PHARMA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IGC PHARMA INC EBITDA is −8.49 M EUR, and current EBITDA margin is −681.12%. See more stats in IGC PHARMA INC financial statements.
Like other stocks, IGS1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IGC PHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IGC PHARMA INC technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IGC PHARMA INC stock shows the neutral signal. See more of IGC PHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.